[DOI] [PubMed] [Google Scholar] 706
The level of glutathione also decreases with age
Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH
Remember, everyones body responds differently to medications, so your experience with semaglutide might not look exactly like someone elses
Were left wondering, How are GLP-1s causing these effects? asked senior author Marc Montminy, a biochemist, physiologist and distinguished professor emeritus at Salk
MillsRJTitmarshDMKoenigXParkerBLRyallJGQuaife-RyanGAet alFunctional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest